| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Rivaroxaban |
| Brand | Xarelto® |
| Indication | Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE. |
| Assessment Process | |
| Rapid review commissioned | 20/11/2017 |
| Rapid review completed | 21/11/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
A full pharmacoeconomic evaluation is not required as rivaroxaban 10mg is reimbursable under the Community Drug Schemes.